VAERS Explorer
Back to explore

Report #2891521

Received Apr 2, 2026

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex
Male
Age
Age unknown
State
Recovered
Recovered
Vaccinated
Onset
Days to onset
Hospital days

Vaccines (1)

TypeNameManufacturerDoseLotRoute / Site
VARZOSZOSTER (SHINGRIX)GLAXOSMITHKLINE BIOLOGICALS1

Symptoms (1)

Sinusitis

Symptom narrative

Sinus infection one day after dose 1; This non-serious case was reported by a other health professional and described the occurrence of sinus infection in a male patient who received Herpes zoster (Shingrix) for prophylaxis. On an unknown date, the patient received the 1st dose of Shingrix .5 ml. On an unknown date, 1 day after receiving Shingrix, the patient experienced sinus infection (Verbatim: Sinus infection one day after dose 1). The outcome of the sinus infection was resolved. It was unknown if the reporter considered the sinus infection to be related to Shingrix. It was unknown if the company considered the sinus infection to be related to Shingrix. Additional Information: GSK Receipt Date: 28-MAR-2026 The reporter mentioned that the patient was not sure if the sinus infection was related to Shingrix. The patient was planning on getting dose 2. The batch number was not provided upon follow- up with the reporter.